Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

British American Tobacco

Comerica

Dominion Energy

Kraft Heinz

Kinder Morgan

AT&T

The legacy telecommunications company has been going through a lengthy restructuring, lowering the dividend, which still checks in at 6.62%.

7 Dividend Stocks to Buy and Hold Forever

Archer-Daniels-Midland Company

AMERISAFE

SSR Mining

Exxon Mobil

ZTO Express

While investors might be tempted to ride the biggest winners of last year, shifting sands may provide a superior outlook for comeback stocks. Just what am I talking about?

7 Stocks Primed for a Spectacular Comeback in 2024

Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has been downgraded by Bank of America (BoA) analysts given the mixed performances of the drugmaker's newly launched products and lack of clarity on long-term growth.  They lowered their rating on the stock from ‘Buy' to ‘Neutral' and slashed their price target from US$68 to US$60.

Bristol-Myers Squibb downgraded on mixed sales performance of new products amid loss of exclusivity concerns

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib.

European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors

RayzeBio Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (NasdaqGM: RYZB) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of RayzeBio will receive $62.50 in cash for each share of RayzeBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Since 2019, Bristol-Myers Squibb has acquired pharmaceutical companies worth more than $115 billion, allowing it to expand its drug portfolio and product candidates in late-stage development. From 2022 to 2023, Bristol-Myers Squibb has won 13 regulatory approvals for Opdivo.

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

Albemarle

Conagra Brands

Dollar General

Devon Energy

Estee Lauder

Enphase Energy

Eversource Energy

Etsy

Hormel Foods

Illumina

Moderna

NextEra Energy

Paycom Software

Pfizer

Insulet

V.F.

Walgreens

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Here are the 20 worst-performing stocks among the S&P 500 in 2023

American Electric Power Company

Black Hills

Enterprise Products Partners

Evergy Inc

L3Harris

Sempra Energy

Tractor Supply

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for further research and possible investment.

10 Dividend Growth Stocks: December 2023

On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equity value of $14 billion.

Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals

The latest trading day saw Bristol Myers Squibb (BMY) settling at $51.22, representing a +0.02% change from its previous close.

Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing

ABM Industries

Franklin Resources

Morningstar

Royal Gold

Schwab US Dividend Equity ETF

ABM Industries extends its 56-year streak of dividend increases with a 2.3% increase.

5 Upcoming Dividend Increases To Start 2024, Including A Dividend King

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

Fusion Pharmaceuticals

Eli Lilly

Point Biopharma Global

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Bristol-Myers Squibb (NYSE: BMY), the giant pharmaceutical company, had a difficult year as its stock tanked. Its shares crashed by over 28% in 2023, becoming one of the top laggards of the S&P 500 index.

After a bruising 2023, Bristol-Myers Squibb (BMY) forges a risky M&A strategy

RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options. It was the second multibillion-dollar acquisition for Bristol Myers Squibb in less than a week.

Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days

Intel

Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive territory.

Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio

Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has made its second major acquisition in the span of a week, this time buying cancer drug developer RayzeBio in a $4.1 billion deal.  The deal values RayzeBio at $62.50 per share.

Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

AstraZeneca

Pharmaceutical giants AstraZeneca plc (NASDAQ:AZN) and Bristol-Myers Squibb Co  (NYSE:BMY) announced new acquisitions today.

Acquisitions Push 2 Pharma Stocks in Opposite Directions

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.

Bristol Myers to buy RayzeBio for about $4.1B

Apple

Karuna Therapeutics Inc

Masimo

Nano Dimension

Stratasys

The holiday shopping season isn't over yet. A 3-D printing company and a major pharmaceuticals maker announced post-Christmas acquisitions Tuesday morning.

Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'

News for Bristol-Myers Stock (BMY)